Federal Register / Vol. 72, No. 155 / Monday, August 13, 2007 / Notices 45253 

more efficiently than current available 

technologies. 

3. The average coverage of Agilent 

oligoarray is 1 per 35kb of human 

genome, while the average coverage of 

the currently described technology is 1 

per 400bp. 

Developmental Status: The 

technology is ready for use. 

Benefits: More than 600,000 cancer 

deaths are estimated to occur in 2007. 

Efficient diagnosis and informed 

decision making will aid in improved 

clinical management of cancer. This 

technology can rapidly diagnose cancer 

and thus help in proper clinical 

management leading to improved 

overall survival and quality of life of 

patients suffering from cancer. The 

current in-vitro diagnostics market is 

valued at $30 billion dollars and 

expected to grow. 

Inventors: Xiaolin Wu, David Munroe, 

Ester Rozenblum, Hongling Liao (NCI/ 

SAIC). 

Patent Status: U.S. Provisional 

Application No. 60/911,411 filed 12 

April 2007 (HHS Reference No. E–122–

2007/0–US–01). 

Licensing Contact: Thomas P. Clouse, 

J.D.; 301/435–4076; 

clouset@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute 

Laboratory of Molecular Technology is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize 

CGH microarrays. Please contact John D. 

Hewes, PhD at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Methods and Compositions for Treating 

Diseases and Disorders Associated with 

Natural Killer T–Cells 

Description of Technology: The 

invention relates to the discovery that 

C12 beta-D-galactosyl ceramide may be 

used to deplete or inactivate NKT cell 

populations. These findings suggest 

methods for using C12 beta-D-galactosyl 

ceramide to treat conditions that would 

benefit from depletion of NKT cells, 

such as certain autoimmune diseases 

(e.g. lupus, MS) and AIDS. 

The presence of NKT cells can be 

associated with either beneficial effects 

or pathology. Deficiencies in NKT cells 

are associated with at least some types 

of autoimmune disease, including type 

1 diabetes and autoimmune gastritis in 

mice. In contrast, NKT cells augment 

autoantibody secretion and lupus 

development in lupus-prone mouse 

models and therefore lupus patients 

may benefit from the depletion of NKT 

cells. The remission state of multiple 

sclerosis (MS) is also associated with 

decreased levels of NKT cells, 

suggesting NKT cell depletion as a 

method of treatment for MS. 

Inventors: John R. Ortaldo and Robert 

H. Wiltrout (NCI). 

Patent Status: 

U.S. Provisional Application No. 60/ 

488,339 filed 17 July 2003 (HHS 

Reference No. E–282–2002/0–US–01). 

PCT Application No. PCT/US2004/ 

22913 filed 16 Jul 2004, which 

published as WO 2005/014008 on 17 

Feb 2005 (HHS Reference No. E–282–

2002/0–PCT–02). 

European Application No. 04778424.4 

filed 16 Jul 2004, which published as 

1653977 on 10 May 2006 (HHS 

Reference No. E–282–2002/0–EP–03). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

P53 and VGEF Regulate Tumor Growth 

of NO2 Expressing Cancer Cells 

Description of Technology: The 

increased expression of nitric oxide 

synthase 2 (NOS2), an inducible enzyme 

that produces nitric oxide (NO), has 

been found in a variety of human 

cancers. It also has been shown that 

NOS2-specific inhibitors can reduce the 

growth of experimental tumors in mice. 

These findings suggest a 

pathophysiological role for NO in the 

development and progression of cancer. 

However, the function of NO and NOS2 

in carcinogenesis is uncertain. NO had 

been found to either inhibit or stimulate 

tumor growth, and high concentrations 

of NO also are known to induce cell 

death in many cell types including 

tumor cells. On the other hand, the 

lower concentrations of NO that are 

found in human tissue can have an 

opposite effect and protect against 

programmed cell death, or apoptosis, 

from various stimuli. The role of NO 

and NOS2 in tumor progression, 

particularly with respect to p53, 

therefore need to be further defined. 

This invention comprises methods of 

screening for modulators of NOS2 

expression in p53 mutant cells, both in 

vivo and in vitro, as well as methods for 

predicting the chemotherapeutic benefit 

of administering NOS2-inhibitors to 

cancer patients. It has been 

demonstrated that NOS2-expressing 

cancer cells with wild-type p53 have 

reduced tumor growth in athymic nude 

mice whereas NOS2-expressing cancer 

cells with mutated p53 have accelerated 

tumor growth. Therefore, this invention 

has potential application for a number 

of cancers that overexpress NOS2 and 

have a high frequency of p53 mutations, 

including breast, brain, head, neck, lung 

and colon cancers. 

Applications: 

1. Method to treat cancer with NOS2 

inhibitors. 

2. Method to screen for NOS2 

modulators. 

3. Method to predict therapeutic 

benefits of NOS2 inhibitors in patients. 

Market: 

1. An estimated 1,444,920 new cancer 

diagnoses in the U.S. in 2007. 

2. 600,000 deaths caused by cancer in 

the U.S. in 2006. 

3. Cancer is the second leading cause 

of death in United States. 

4. It is estimated that market for 

cancer drugs would double to $50 

billion a year in 2010 from $25 billion 

in 2006. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Stefan Ambs and Curt 

Harris (NCI). 

Publications: 

1. JE Goodman et al. Nitric oxide and 

p53 in cancer-prone chronic 

inflammation and oxyradical overload 

diseases. Environ Mol Mutagen. 

2004;44(1):3–9. 

2. LJ Hofseth et al. Nitric oxide in 

cancer and chemoprevention. Free 

Radic Biol Med. 2003Apr 15;34(8):955–

968. 

Patent Status: 

U.S. Patent Application No. 11/ 

195,006 filed 01 Aug 2005 (HHS 

Reference No. E–223–1998/0–US–04). 

U.S. Patent Application No. 09/ 

830,977 filed 02 May 2001 (HHS 

Reference No. E–223–1998/0–US–03). 

PCT Patent Application No. PCT/ 

US1999/27410 filed 17 Nov 1998 (HHS 

Reference No. E–223–1998/0–PCT–02). 

U.S. Provisional Patent Application 

No. 60/109,563 filed 23 Nov 1998 (HHS 

Reference No. E–223–1998/0–US–01). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Dated: August 3, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–15749 Filed 8–10–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Clinical Center; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 


jlentini on PROD1PC65 with NOTICES
45254 Federal Register / Vol. 72, No. 155 / Monday, August 13, 2007 / Notices 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the NIH 

Advisory Board for Clinical Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the contact person listed below in 

advance of the meeting. 

This meeting will be closed to the 

public in accordance with provisions set 

forth in section 552b(c)(6), Title 5 

U.S.C., as amended to discuss personnel 

matters, the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. This 

meeting is partially closed to the public. 

Name of Committee: NIH Advisory Board 

for Clinical Research. 

Date: September 21, 2007. 

Open: 10 a.m. to 1 p.m. 

Agenda: To review the Clinical Center’s 

operating plan and provide updates on 

selected organizational initiatives. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board, Room 4-2551, Bethesda, MD 20892. 

Closed: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate personnel 

matters. 

Place: National Institutes of Health, 

Building 10, 10 Center Drive, CRC Medical 

Board, Room 4–2551, Bethesda, MD 20892. 

Contact Person: Maureen E. Gormley, 

Executive Secretary, Mark O. Hatfield 

Clinical Research Center, National Institutes 

of Health, Building 10, Room 6–2551, 

Bethesda, MD 20892, (301) 496–2897. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the contact person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Dated: August 6, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3923 Filed 8–10–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Alcohol Abuse and Alcoholism Special 

Emphasis Panel, Neuroscience and Alcohol. 

Date: October 2, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Beata Buzas, PhD, 

Scientific Review Administrator, National 

Institutes on Alcohol Abuse and Alcoholism, 

National Institutes of Health, 5635 Fishers 

Lane, Rm 3041, Rockville, MD 20852, 301–

443–0800. bbuzas@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.271, Alcohol Research 

Career Development Awards for Scientists 

and Clinicians; 93.272, Alcohol National 

Research Service Awards for Research 

Training; 93.273, Alcohol Research Programs; 

93.891, Alcohol Research Center Grants, 

National Institutes of Health, HHS) 

Dated: August 6, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–3924 Filed 8–10–07; 8:45am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Mental Health Services; 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

Center for Mental Health Services 

(CMHS) National Advisory Council will 

meet on August 14, 2007 from 2 p.m. to 

3 p.m. via teleconference. 

The meeting will include the review, 

discussion and evaluation of grant 

applications. Therefore the meeting will 

be closed to the public as determined by 

the Administrator, SAMHSA, in 

accordance with Title 5 U.S.C. 

552b(c)(6) and 5 U.S.C. App. 2, Section 

10(d). 

Substantive program information, a 

summary of the meeting and a roster of 

Council members may be obtained as 

soon as possible after the meeting, either 

by accessing the SAMHSA Committee 

Web site at http://www.nac.samhsa.gov, 

or by contacting the CMHS National 

Advisory Council Executive Secretary, 

Dianne McSwain (see contact 

information below). 

Committee Name: Substance Abuse 

and Mental Health Services 

Administration, Center for Mental 

Health Services National Advisory 

Council. 

Date/Time/Type: August 14, 2007, 

from 2 p.m. to 3 p.m.: Closed. 

Place: 1 Choke Cherry Road, 

Conference Room 6–1060, Rockville, 

Maryland 20852. 

Contact: Dianne McSwain, M.S.W., 

Executive Secretary, SAMHSA CMHS 

National Advisory Council, 1 Choke 

Cherry Rd., Rm. 6–1063, Rockville, 

Maryland 20857, Telephone: (240) 276–

1828, E-mail: 

dianne.mcswain@samhsa.hhs.gov. 

Dated: August 7, 2007. 

Toian Vaughn, 

Committee Management Officer, Substance 

Abuse and Mental Health Services 

Administration. 

[FR Doc. E7–15791 Filed 8–10–07; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Center for Substance Abuse 

Prevention; Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Administration (SAMHSA) Center for 

Substance Abuse Prevention (CSAP) 

National Advisory Council (NAC) will 

meet on August 28, 2007. 

The meeting is open and will include 

discussion of the Center’s policy issues 

and current administrative, legislative, 

and program developments. 


jlentini on PROD1PC65 with NOTICES